Immediate Postpartum Nexplanon Placement in Opioid Dependent Women

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Opiate AddictionPregnancyContraceptive BehaviorSexual Behavior
Interventions
DRUG

Nexplanon (etonogestrel contraceptive implant)

Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.

DRUG

Standard postpartum contraceptive care

Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.

Trial Locations (1)

15213

Magee-Womens Hospital of UPMC, Pittsburgh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT02657148 - Immediate Postpartum Nexplanon Placement in Opioid Dependent Women | Biotech Hunter | Biotech Hunter